Bausch + Lomb Corporation announced that Health Canada has approved the enVista®? Envy?? full visual range intraocular lens (IOL).

This is the first global regulatory approval of the new lens, which offers a full range of vision with excellent dys photopsia tolerance on the widely used enVista IOL platform. A multicenter, randomized, and controlled clinical trial demonstrated excellent long-term outcomes with the enVista Envy IOL in Canada. On average, 93% of patients reported little to no bothersomeness for dys photopsia (glare, halo, starbursts), touting an impressive tolerance profile overall.

Additionally, 94% of patients reported little to No difficulty viewing close objects, while delivering excellent distance vision horizon-free post-surgery with 4 diopters of continuous visual range. The enVista Envy features ActivSync Optic Intelligent Energy Distribution, optimizing vision in every lighting condition, and ClearPath technology, which helps reduce light scattering. Low-Cyl toric technology allows the enVista Envy toric lens to simultaneously treat presbyopia and low amounts of astigmatism (0.9D IOL Plane - Canada), while offering more precision with 0.5D steps (or less) throughout the cylinder range.

enVista Envy IOLs will be commercially available in Canada mid-June. Bausch + Lomb is also in the process of seeking regulatory approvals for the lens in additional markets, including the U.S. and Europe.